key: cord-0711390-oshmehqb
authors: Hulpia, Fabian; Balzarini, Jan; Schols, Dominique; Andrei, Graciela; Snoeck, Robert; Van Calenbergh, Serge
title: Exploring the purine core of 3′-C-ethynyladenosine (EAdo) in search of novel nucleoside therapeutics
date: 2016-04-15
journal: Bioorg Med Chem Lett
DOI: 10.1016/j.bmcl.2016.03.005
sha: 2ddd476f3ef7e85e92ede22cfe536ff7786d131d
doc_id: 711390
cord_uid: oshmehqb

A series of new nucleoside analogues based on a C-3 branched ethynyl sugar derivative as present in 3′-C-ethynylcytidine (ECyd) and -adenosine (EAdo), combined with modified purine bases was synthetized and evaluated against a broad array of viruses and tumour cell lines. The pronounced cytostatic activity of EAdo was confirmed. EAdo and its 2,6-diaminopurine analogue showed inhibitory activity against vaccinia virus (EC(50): 0.31 and 51 μM, respectively). Derivative 10 on the other hand was found active against varicella zoster virus (EC(50): 4.68 μM).

All reagents and solvents were from standard commercial sources and of analytical grade. Unless otherwise specified, they were used as received. All moisture sensitive reactions were carried out under an argon atmosphere. Analytical TLC was performed om Machery-Nagel® precoated F254 aluminum plates and were visualized by UV, basic aq. KMnO4 or sulfuric acid-anisaldehyde spray. Column chromatography was performed using Davisil® (40 -63 µm) or on a Reverleris X2 (Grace) automated flash unit. NMR spectra were recorded on a Varian Mercury 300 MHz spectrometer. Chemical shifts (δ) are given in ppm and spectra are referenced to the residual solvent peak. NMR signals were assigned by means of gCOSY and gHSQC measurements. After glycosylation reactions, stereo-and regiochemistry was proven by means of gHMBC and NOESY. Exact mass measurements were performed on a Waters LCT Premier XETM Time of Flight (ToF) mass spectrometer equipped with a standard electrospray (ESI) and modular Lockspray TM interface. Samples were infused in a MeCN / water (1:1) + 0.1 % formic acid mixture at 100 µL / min.

Biological evaluation

The compounds were evaluated against the following viruses: herpes simplex virus type 1 (HSV-1) strain KOS, thymidine kinase-deficient (TK−) HSV-1 KOS strain resistant to ACV (ACVr), herpes simplex virus type 2 (HSV-2) strains Lyons and G, varicella-zoster virus (VZV) strain Oka, TK− VZV strain 07−1, human cytomegalovirus (HCMV) strains AD-169 and Davis, vaccinia virus Lederle strain, adenovirus-2, respiratory syncytial virus (RSV) strain Long, vesicular stomatitis virus (VSV), Coxsackie B4, parainfluenza 3, influenza virus A (subtypes H1N1, H3N2), influenza virus B, Sindbis, reovirus-1, Punta Toro, human immunodeficiency virus type 1 strain IIIB and human immunodeficiency virus type 2 strain ROD. The antiviral, other than anti-HIV, assays were based on inhibition of virus-induced cytopathicity or plaque formation in human embryonic lung (HEL) fibroblasts, African green monkey cells (Vero), human epithelial cells (HeLa) or Madin-Darby canine kidney cells (MDCK) . Confluent cell cultures in microtiter 96-well plates were inoculated with 100 CCID50 of virus (1 CCID50 being the virus dose to infect 50 % of the cell cultures) or with 20 plaque forming units (PFU) (VZV) in the presence of varying concentrations of the test compounds. Viral cytopathicity or plaque formation was recorded as soon as it reached completion in the control virus-infected cell cultures that were not treated with the test compounds. Antiviral activity was expressed as the EC50 or compound concentration required to reduce virus-induced cytopathogenicity or viral plaque formation by 50 %. Cytotoxic concentration was expressed as the MCC or minimal cytotoxic concentration being the compound concentration that was required to afford a microscopically visible alteration of cell morphology. Assays involving HCMV and VZV were performed as described in literature. 1

Inhibition of HIV-1 (NL4.3)-and HIV-2 (ROD)-induced cytopathicity in CD4+ T-lymphocyte MT-4 cell cultures was measured in microtiter 96-well (200-µL) plates containing ~ 106 MT-4 cells / mL and a variety of test compound concentrations. Thirty minutes after exposure of the MT-4 cells to the test compounds, the cell cultures were infected with HIV-1 (NL4.3) at 3 pg p24 / well (or 60 pg / mL). The virus dose affords full cytopathicity after 4 to 5 days of incubation in the absence of the test compounds (control). After 4 to 5 days incubation at 37°C in a CO2-controlled atmosphere, cytopathicity was microscopically recorded. Concomitantly, 100 µL of the supernatants of each of the cell cultures was removed from the wells and 50 µl of a MTS solution was added to the remaining cell suspension. After 2 to 3 hr incubation at 37°C, 50 µL Triton X-100 (0.5 %) was added and absorbancy measured using a Soft Max Pro program.

All assays were performed in 96-well microtiter plates. To each well were added (5−7.5) × 10 4 tumor cells and a given amount of the test compound. The cells were allowed to proliferate for 48 h (murine leukemia L1210 cells) or 72 h (human lymphocytic CEM and human cervix carcinoma HeLa cells) at 37 °C in a humidified CO2-controlled atmosphere. At the end of the incubation period, the cells were counted in a Coulter counter. The IC50 (50 % inhibitory concentration) was defined as the concentration of the compound that inhibited cell proliferation by 50 %. 2 1,2-O-isopropylidene-α-D-xylofuranose (11.41 g, 60 mmol) was dissolved in anhydrous DMF (300mL) under Argon. Next imidazole (10.21 g, 150 mmol) was added and the mixture was cooled in an ice bath. After 15 min, TBDPSiCl (20.30 mL, 78 mmol) was added and the ice bath removed. TLC analysis (25 % EA / Hex; Rf = 0.33) showed full conversion after 1 hour. Water was added and the mixture evaporated till dryness. The residue was taken up in EA (300 mL) and water (150 mL). The layers were separated and the organic layer was sequentially washed with sat. NH4Cl sol. (150 mL), sat. NaHCO3 sol. (150 mL) and brine (150 mL). The organic layer was dried over Na2SO4, filtered and evaporated till dry. The mixture was purified by column chromatography (10 % → 30 % EA / Hex). The product (25.5 g, 59.5 mmol) was isolated as white waxy solid (99% yield). 

I (18 g, 42 mmol) was dissolved in anhydrous DMSO (130 mL) under argon. Next, Ac2O (15.88 mL, 168 mmol) was added and the resulting solution stirred at rt for 2 days. Then, the mixture was poured into ice water (200 mL) and EA (400 mL). The layers were separated and the organic layer sequentially washed with sat. NaHCO3 sol. (200 mL) and brine (150 mL). The organic layer was dried over Na2SO4, filtered and evaporated till dry. The oily residue was co-evaporated with toluene (3 x 40 mL). Next, the residue was re-dissolved in anhydrous THF (125 mL) under argon and cooled in an ice bath. Subsequently, ethynylMgBr (0.5 M in THF; 100 mL, 50 mmol) was added dropwise via an addition funnel. After complete addition the mixture was allowed to warm to rt, after which TLC (25 % EA / Hex, Rf= 0.39) showed full conversion of the intermediate ketone. The mixture was quenched by adding sat. NH4Cl sol. (50 mL). Next, the mixture was extracted with EA (300 mL) and water (100 mL). The layers were separated and the water layer extracted with EA (2 x 100 mL). Organic layers were combined, dried over Na2SO4, filtered and evaporated till dry. The residue was co-evaporated with Celite® and purified by column chromatography (10 % → 25 % EA / Hex) to give a waxy white solid (16.23 g, 35.85 mmol) in 85 % yield. 

II (12 g, 26.5 mmol) was dissolved in THF (130 mL). Then, a TBAF solution (1M in THF; 28.5 mL, 28.5 mmol) was added and the mixture was stirred at rt for 1 hour. Next, the mixture was evaporated till dry and the residue purified by column chromatography (25 % → 90 % EA / Hex) to yield III as a white solid (5.11 g, 23.8 mmol) in 90 % yield. 

III (8.45 g, 39.4 mmol) and DMAP (0.48 g, 3.94 mmol) were dissolved in anhydrous pyridine (180 mL) under argon, after which Ac2O (15.1 mL, 160 mmol) was added. The resulting mixture was stirred at rt for 2 days. Then, ice water (15 mL) was added, evaporated and co-evaporated with toluene (3 x 25 mL). The residue was partitioned between water (100 mL) and EA (250 mL). The organic layer was washed with sat. NaHCO3 sol. (100 mL) and brine (75 mL). The organic layer was dried over Na2SO4, filtered and evaporated till dry. The residue was dissolved in a mixture of TFA / water (8/2; 120 mL / 30 mL) and stirred at rt for 3 hours. Next, the solvent was removed, co-evaporated with toluene (3 x 25 mL) and pyridine (2 x 25 mL). The remaining oil was dissolved in anhydrous pyridine (180 mL) and DMAP (0.48 g, 3.94 mmol) was added, followed by Ac2O (15.1 mL, 160 mmol). The mixture was stirred at rt overnight after which ice water (15 mL was added) and evaporated till dry. The residue was co-evaporated with toluene (3 x 25 mL), after which it was taken up into EA (250 mL) and water (100 mL). Next, the organic layer was washed with sat. NaHCO3 sol. (75 mL) and brine (75 mL). The organic layer was dried over Na2SO4, filtered and co-evaporated with Celite®. Purification by column chromatography (25 % EA / Hex) yielded 4 as a slight yellow oil (12.2 g, 35.7 mmol) in 90 % yield (over 3 steps). 

N 6 -benzoyl-adenine (0.239 g, 1.0 mmol) was refluxed in HMDS (15 mL) overnight under argon in the presence of a catalytic amount of (NH4)2SO4 (0.010 g, 0.076 mmol). Then, the solution was cooled to rt and the excess of HMDS evaporated till dry. The resulting oil was taken up into anhydrous acetonitrile (2 mL) and stirred under argon after which 4 (0.171 g, 0.50 mmol) was added as a solution in acetonitrile (2 mL). Next, the resulting solution was heated to reflux, after which TMSOTf was added (0.14 mL, 0.75 mmol) and the mixture stirred for 3 hours. After cooling to rt, the solution was poured in sat. NaHCO3 (10 mL) and extracted 3 x with 15 mL of DCM. Organic layers were combined, dried over Na2SO4, filtered and evaporated till dryness. Next, the resulting oil was directly deprotected by stirring at rt in sat. NH3 in MeOH (7N) (15 mL) for 2 days. The mixture was subsequently co-evaporated with Celite®. Purification by column chromatography (2 -12 % MeOH / DCM) gave 1 (0.059 g, 0.2 mmol) as a white solid in 40 % yield. 2,6-dichloro-9H-purine (1.757 g, 9.3 mmol) was refluxed in HMDS (75 mL) overnight under argon in the presence of a catalytic amount of (NH4)2SO4 (0.03 g, 0.227 mmol). Then, the solution was cooled to rt and the excess of HMDS evaporated till dry. The resulting oil was taken up into anhydrous 1,2-dichloroethane (50 mL) and stirred under argon. Then, 4 was added as a solution in anhydrous 1,2-dichloroethane (20 mL) via syringe. The mixture was subsequently heated to reflux, after which TMSOTf (1.27 mL, 6.99 mmol) was added. Reflux was continued for 3.5 h, and then cooled to rt. The mixture was poured into 40 mL sat. NaHCO3 and 50 mL DCM. The layers were separated and the water layer extracted with DCM (2 x 50 mL). The organic layers were combined, dried over Na2SO4, filtered and co-evaporated with Celite®. Purification by column chromatography (2.5 % → 5 % acetone / DCM) gave 6 (1.57 g, 3.34 mmol) as a white foam in 72 % yield. 

6 (0.23 g, 0.5 mmol) was dissolved in MeOH (10 mL). Next, a solution of NaOMe (5.4 M) in MeOH (0.37 mL, 2 mmol) was added after which the mixture was stirred at rt for 30 minutes. Then, Amberlite® IR120 was added. After neutralization, the mixture was filtered, washed with MeOH and evaporated to dryness. Next, the mixture was coevaporated with Celite® and purified by column chromatography (12 g) (1 % → 6 % MeOH / DCM) gave 8 as a white solid (0.122 g, 0.359 mmol) in 72 % yield. 

6 (0.235 g, 0.5 mmol) was dissolved in EtOH (7.5 mL) and cyclopentylamine (0.295 mL, 3 mmol) was added. Next, the mixture was refluxed for 3 hours, after which it was evaporated till dryness. Next, a sat. solution of NH3 in MeOH (7N) (7.5 mL) was added and the mixture stirred at rt overnight. then, the mixture was evaporated, co-evaporated with Celite® and purified by column chromatography (5 % → 10 % MeOH / DCM) to yield 9 (0.167 g, 0.424 mmol) as a white solid in 85 % yield. 

6 (0.212 g, 0.452 mmol) was dissolved in EtOH (7.5 mL) and 3chlorobenzylamine (0.361 mL, 2.95 mmol) was added. Next, the mixture was refluxed for 7 hours, after which it was evaporated till dryness. Next, a sat. solution of NH3 in MeOH (7N) (7.5 mL) was added and the mixture stirred at rt overnight. then, the mixture was evaporated, co-evaporated with Celite® and purified by column chromatography (2.5 % → 5 % MeOH / DCM) to yield 10 (0.157 g, 0.349 mmol) as a white solid in 77 % yield. 

2-amino-6-dichloro-9H-purine (0.9 g, 5.3 mmol) was refluxed in HMDS (23 mL) overnight under argon in the presence of a catalytic amount of (NH4)2SO4 (0.03 g, 0.227 mmol). Then the solution was cooled to rt and the excess of HMDS evaporated till dry. The resulting oil was taken up into anhydrous 1,2-dichloroethane (25 mL) and stirred under argon. Then, 4 (0.910 g, 2.66 mmol) was added as a solution in anhydrous 1,2-dichloroethane (15 mL) via syringe. The mixture was subsequently heated to reflux, after which TMSOTf (0.72 mL, 4.0 mmol) was added. Refluxing was continued for 3.5 h, and then cooled to rt. The mixture was poured into 40 mL sat. NaHCO3 and 50 mL DCM. The layers were separated and the water layer extracted with DCM (2 x 50 mL). The organic layers were combined, dried over Na2SO4, filtered and co-evaporated with Celite®. Purification by column chromatography (10 % → 15 % acetone / DCM) gave 11 (0.52 g, 1.15 mmol) as a white foam in 43 % yield. 

11 (0.124 g, 0.274 mmol) was dissolved in sat. NH3 in MeOH (7N) (8 mL) and stirred at rt for 10 days. Next, the solvent was removed and co-evaporated with Celite®. Purification by column (4 g) (12 % MeOH / DCM) gave 12 as a white solid (0.021 g, 0.069 mmol) in 25 % yield. 

11 (0.2 g, 0.45 mmol) was dissolved in MeOH (10 mL) and a solution of NaOMe (5.4M) in MeOH (0.1 mL, 0.5 mmol) was added after which the mixture was stirred at rt for 30 minutes. Then, Amberlite® IR120 was added. After neutralization, the mixture was filtered, washed with MeOH and evaporated to dryness. Next, the mixture was co-evaporated with Celite® and purified by column chromatography (7 % → 10 % MeOH / DCM) to yield 13 (0.09 g, 0.278 mmol) as a white solid in 63 % yield. 

20 (0.038 g, 0.085 mmol) was dissolved in MeOH (5 mL). Next, a solution of NaOMe (5.4M) in MeOH (0.079 mL, 0.425 mmol) was added after which the mixture was stirred at rt for 30 minutes. Then, Amberlite® IR120 was added. After neutralization, the mixture was filtered, washed with MeOH and evaporated to dryness. Next, the mixture was co-evaporated with Celite® and purified by column chromatography (0 % → 10 % MeOH / DCM) to yield 14 (0.017 g, 0.053 mmol) as a white solid in 62 % yield. 

21 (0.09 g, 0.195 mmol) was dissolved in MeOH (7 mL) and NaOMe (5.4 M solution in MeOH) (0.180 mL, 0.973 mmol) was added. Next, the mixture was stirred for 30 minutes and subsequently neutralized by adding Amberlite® IR120. The mixture was filtered and evaporated till dryness. Next, the residue was co-evaporated with Celite® and purified by column (4 g) (0.5 % → 7.5 % MeOH / DCM), to yield 15 as a white solid (0.043 g, 0.127 mmol) in 66 % yield. 11 (0.18 g, 0.4 mmol) was dissolved in MeOH (5 mL). Next, a solution of NaOMe (5.4M) in MeOH (0.37 mL, 2 mmol) was added after which the mixture was stirred at rt for 24 h. Next, an additional 0.15 mL of NaOMe solution was added together with 5 mL of MeOH and refluxed until full conversion was observed (24 h). Then, the mixture was cooled to rt and neutralized with Amberlite® IR120. Next, the mixture was filtered, washed with MeOH and evaporated to dryness. Next, the residue was co-evaporated with Celite® and purified by column (5 % MeOH / DCM) to give the cyclized product 16 (0.049 g, 0.152 mmol) in 38 % yield. 6 (0.159 g, 0.465 mmol) was dissolved in MeOH (7 mL). Next, a solution of NaOMe (5.4M) in MeOH (0.265 mL, 1.43 mmol) was added after which the mixture was stirred at rt for 24 h. An additional 0.15 mL of NaOMe solution was added together with 5 mL of MeOH and refluxed until full conversion was observed (overnight). Then, the mixture was cooled to rt and neutralized with Amberlite® IR120. Next, the mixture was filtered, washed with MeOH and evaporated to dryness. Next, the residue was co-evaporated with Celite® and purified by column (3 % MeOH / DCM) to give the cyclized product 17 (0.045 g, 0.134 mmol) in 29 % yield. 

Freshly cut sodium wire (2.03 g, 88.5 mmol) was portion wise added to anhydrous MeOH (60 mL) under argon. After the wire was fully dissolved, 2-amino-6-chloro-9H-purine (3 g, 17.69 mmol) was added and the resulting mixture refluxed for 2.5 days. Next, the mixture was cooled to rt and resulting precipitate filtered. The filtrate was neutralized with acetic acid and evaporated till dry. The resulting solid was recrystallized from water to yield 18 as a white solid (2.65 g, 16.05 mmol) in 91 % yield. 1 H NMR (300 MHz, DMSO-d6) δ: 3.95 (s, 3H, OCH3), 6.23 (br s, 2H, NH2), 7.82 (s, 1H, H-8), 12.43 (br s, 1H, N-H). dichloroethane (5.3 mL) via syringe. The mixture was subsequently heated to reflux, after which TMSOTf (0.151 mL, 0.833 mmol) was added. Refluxing was continued for 45 min, and then cooled to rt. The mixture was poured into 10 mL sat. NaHCO3 and 15 mL DCM. The layers were separated and the water layer extracted with DCM (2 x 15 mL). The organic layers were combined, dried over Na2SO4, filtered and co-evaporated with Celite®. Purification by column chromatography (5 % acetone / DCM) gave 21 (0.092 g, 0.199 mmol) as a white foam in 36 % yield. 

HRMS (ESI): calculated for C6H8N5O

100 mmol) was portionwise added to anhydrous MeOH (40 mL) under argon. After the wire was fully dissolved, 2,6-dichloro-9H-purine (1.89 g, 10 mmol) was added and the resulting mixture refluxed for 3.5 days. Next, the mixture was cooled to rt and neutralized with acetic acid

18 (0.183 g, 1.11 mmol) was refluxed in HMDS (10 mL) overnight under argon in the presence of a catalytic amount of (NH4)2SO4 (0.010 g, 0.076 mmol). Then, the solution was cooled to rt and the excess of HMDS evaporated till dry. The resulting oil was taken up into anhydrous 1,2-dichloroethane (3 mL) and stirred under argon. Then, 4 (0.19 g, 0.555 mmol) was added as a solution in anhydrous 1,2-dichloroethane (5.3 mL) via syringe. The mixture was subsequently heated to reflux, after which TMSOTf (0.151 mL, 0.833 mmol) was added. Refluxing was continued for 1.5 h, and then cooled to rt. The mixture was poured into 10 mL sat. NaHCO3 and 15 mL DCM. The layers were separated and the water layer extracted with DCM (2 x 15 mL). The organic layers were combined, dried over Na2SO4, filtered and co-evaporated with Celite®

13 (s, 3H, CH3), 2.19 (s, 3H, CH3), 2.82 (s, 1H, ethynyl-H)

75 MHz, CDCl3) δ: 20.57 (acetyl-CH3), 20.97 (acetyl-CH3)

Synthesis of 2',3',5'-tri-O-acetyl-3'-C-ethynyl-N9-β-D-ribofuranosyl-2,6-dimethoxypurine (21) 19 (0.2 g, 1.11 mmol) was refluxed in HMDS (10 mL) overnight under argon in the presence of a catalytic amount of (NH4)2SO4 (0.010 g, 0.076 mmol). Then, the solution was cooled to rt and the excess of HMDS evaporated till dry. The resulting oil was taken up into anhydrous 1,2-dichloroethane (3 mL) and stirred under argon

Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of l-ascorbic or imino-l-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations

Independent Generation and Characterization of a C2'-Oxidized Abasic Site in Chemically Synthesized Oligonucleotides

Synthesis and biological evaluation of nucleobase-modified analogs of the anticancer compounds 3′-C-ethynyluridine (EUrd) and 3′-Cethynylcytidine (ECyd)

Nucleosides and Nucleotides. 158. 1-(3-C-Ethynyl-β-d-ribo-pentofuranosyl)-cytosine, 1-(3-C-Ethynyl-β-d-ribo-pentofuranosyl)uracil, and Their Nucleobase Analogues as New Potential Multifunctional Antitumor Nucleosides with a Broad Spectrum of Activity

An efficient synthesis of substituted cytosines and purines under focused microwave irradiation